The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 26313252 |
22 |
Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. |
Astrazeneca |
| 26291341 |
66 |
Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity. |
Astrazeneca |
| 22205779 |
11 |
Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro. |
University of Oslo |
| 22645092 |
15 |
Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs. |
Pfizer |
| 22511346 |
1 |
Interaction of lapatinib with cytochrome P450 3A5. |
National University of Singapore |
| 25751283 |
79 |
Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities. |
Purdue University |
| 24712661 |
47 |
Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptorß agonist in clinical trials for the treatment of dyslipidemia. |
Madrigal Pharmaceuticals |
| 16248836 |
154 |
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. |
F. Hoffmann-La Roche |
| 22749190 |
23 |
Wake-promoting agents: search for next generation modafinil: part IV. |
Cephalon (France) |
| 22341942 |
18 |
Wake-promoting agents: search for next generation modafinil: part II. |
Cephalon |
| 22264486 |
62 |
Imidazopyridines as selective CYP3A4 inhibitors. |
The Scripps Research Institute |
| 32452679 |
53 |
Design, Synthesis, and Evaluation of a Series of Novel Super Long-Acting DPP-4 Inhibitors for the Treatment of Type 2 Diabetes. |
Haisco Pharmaceutical Group |
| 32248693 |
73 |
Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria. |
University of Washington |
| 32302132 |
74 |
Design and Characterization of the First Selective and Potent Mechanism-Based Inhibitor of Cytochrome P450 4Z1. |
University of Washington |
| 32031803 |
8 |
Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation. |
Lindsley F. Kimball Research Institute |
| 32208614 |
7 |
CN128: A New Orally Active Hydroxypyridinone Iron Chelator. |
Zhejiang University |
| 30638874 |
64 |
Discovery of new indole-based acylsulfonamide Na |
Bristol-Myers Squibb Research and Development |
| 30623649 |
13 |
Discovery of Novel Pyruvate Dehydrogenase Kinase 4 Inhibitors for Potential Oral Treatment of Metabolic Diseases. |
Gwangju Institute of Science and Technology |
| 31965799 |
14 |
Clobetasol Propionate Is a Heme-Mediated Selective Inhibitor of Human Cytochrome P450 3A5. |
St. Jude Children'S Research Hospital |
| 30067909 |
126 |
Identification of ABX-1431, a Selective Inhibitor of Monoacylglycerol Lipase and Clinical Candidate for Treatment of Neurological Disorders. |
Abide Therapeutics |
| 24900702 |
8 |
Metabolically Stable tert-Butyl Replacement. |
Novartis Institutes For Biomedical Research |
| 23462713 |
20 |
Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi. |
Epichem |
| 22536986 |
12 |
Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease. |
Epichem |
| 29202402 |
24 |
Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors. |
Keimyung University |
| 29886732 |
300 |
Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties. |
Dart Neuroscience |
| 29259755 |
55 |
Discovery of JTZ-951: A HIF Prolyl Hydroxylase Inhibitor for the Treatment of Renal Anemia. |
Japan Tobacco |
| 29724589 |
40 |
Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism. |
Mitsubishi Tanabe Pharma |
| 28368581 |
82 |
Identification of the Clinical Candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist. |
Corcept Therapeutics |
Search and Browse
